Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis
-
Published:2021-04
Issue:
Volume:
Page:
-
ISSN:2405-4569
-
Container-title:European Urology Focus
-
language:en
-
Short-container-title:European Urology Focus
Author:
Wenzel MikeORCID,
Würnschimmel Christoph,
Nocera Luigi,
Collà Ruvolo Claudia,
Tian Zhe,
Shariat Shahrokh F.,
Saad Fred,
Briganti Alberto,
Tilki Derya,
Graefen Markus,
Kluth Luis A.,
Roos Frederik C.,
Mandel Philipp,
Chun Felix K.H.,
Karakiewicz Pierre I.
Funder
University of Frankfurt
Reference44 articles.
1. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007
2. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis;Wallis;Eur Urol,2018
3. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis;Tan;Prostate Cancer Prostat Dis,2018
4. New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis;Marchioni;J Urol,2020
5. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape;Kinsey;Cancer J,2020
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献